by katehumphrey | Mar 27, 2024 3:15 pm | Biotechnology, Private Equity |
Highbridge Capital Management, based in New York City, announced on March 27 that it entered into an agreement to acquire Gamida Cell, an Israeli biotechnology company. The agreement will see Highbridge Capital Management convert $75 million of existing unsecured convertible senior notes into equity in Gamida as well as supply $30 million...
Read More »